Results 121 to 130 of about 28,689 (318)

Taiwan consensus on pulmonary chronic graft‐versus‐host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM)

British Journal of Haematology, EarlyView.
Summary Pulmonary chronic graft‐versus‐host disease (cGVHD), particularly bronchiolitis obliterans syndrome (BOS), is a severe complication of allogeneic haematopoietic stem cell transplantation (allo‐HSCT) with significant morbidity and mortality.
Xavier Cheng‐Hong Tsai, Zong‐Han Yao, Shu‐Wei Chou, Han‐Chung Hu, Yi‐Chang Liu, Chia‐Hung Chen, Su‐Peng Yeh, Wei‐Chang Huang, Tung‐Liang Lin, Tsung‐Ming Yang, Ching‐Han Lai, Hsin‐Kuo Ko, Yao‐Wen Kuo, Hsao‐Hsun Hsu, Shih‐Lung Cheng, Chi‐Cheng Li, Bor‐Sheng Ko, Hao‐Chien Wang, on behalf of the Taiwan Society of Blood and Marrow Transplantation and Taiwan Society of Pulmonary and Critical Care Medicine   +18 more
wiley   +1 more source

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib

Case Reports in Hematology, 2016
Ruxolitinib is widely in use for treatment of myeloproliferative disorders. It causes inhibition of the Janus kinase (JAK) signal transducer and activation of transcription (STAT) pathway, which plays a key role in the underlying pathophysiology of ...
Maheen Z. Abidi, Javeria Haque, Parvathi Varma, Horatiu Olteanu, Guru Subramanian Guru Murthy, Binod Dhakal, Parameswaran Hari   +6 more
doaj   +1 more source

Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report

Turkish Journal of Hematology, 2015
A 67-year-old male patient who was diagnosed with primary myelofibrosis 4 years ago did not respond to conventional therapies. The splenomegaly progressively increased, which caused spleen infarctions and led to the decision to perform a splenectomy ...
Meltem Aylı, Muhit Özcan, Güldane Cengiz Seval   +2 more
doaj   +1 more source

Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid‐refractory acute graft‐versus‐host disease treatment

British Journal of Haematology, EarlyView.
Summary Steroid‐refractory acute graft‐versus‐host disease (SR‐aGvHD) remains a significant challenge after haematopoietic cell transplantation (HCT). While ruxolitinib (RUX) has shown efficacy for SR‐aGvHD, failure predictors are poorly defined. We assessed 78 patients from six Canadian centres who received RUX for SR‐aGvHD. Failure‐free survival (FFS)
Sergio Rodriguez‐Rodriguez, Nihar Desai, Carol Chen, Kareem Jamani, Catherine Sohier‐Poirier, Christopher Lemieux, Jennifer White, Mohamed Elemary, Michael Kennah, Tommy Alfaro Moya, Eshrak Al‐Shaibani, Igor Novitzky‐Basso, Ivan Pasic, Arjun Datt Law, Fotios V. Michelis, Auro Viswabandya, Rajat Kumar, Jonas Mattsson, Dennis Dong Hwan Kim   +18 more
wiley   +1 more source

Ruxolitinib for myelofibrosis therapy: current context, pros and cons [PDF]

, 2012
Animesh Pardanani
openalex   +1 more source

“Nomen Omen: The Myth of God Janus”

JEADV Clinical Practice, EarlyView.
Alba Guglielmo
wiley   +1 more source

The impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation

British Journal of Haematology, EarlyView.
Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2V61F VAF of 48.5% from baseline. In patients that discontinued treatment, the JAK2V617F VAF at the time of treatment discontinuation was the best indicator of durable remission over the 6‐month follow‐up period.
Ryan Brown, Rebekah Bennett, Clare Crean, Andrew Hindley, Julie McGimpsey, Nicholas Cunningham, Aaron Niblock, Suzanne McPherson, Kathryn Boyd, Allister Foy, Ciaren Graham, Graeme Greenfield, Mary Frances McMullin, Mark A. Catherwood   +13 more
wiley   +1 more source

Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study

The Clinical Respiratory Journal
Introduction This expanded access program (EAP) provided ruxolitinib (oral, selective Janus kinase [JAK]1/JAK2 inhibitor) for emergency treatment of COVID‐19–associated cytokine storm in patients eligible for hospitalization (NCT04355793).
Jeffrey Weinstein, Nikhil Jagan, Shawnta Lorthridge‐Jackson, J. E. Hamer‐Maansson, Peg Squier   +4 more
doaj   +1 more source

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial [PDF]

, 2013
Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John Catalano, Michael W. Deininger, Alan L. Shields, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Thomas Hare, Susan Erickson‐Viitanen, William Sun, Victor Sandor, Richard S. Levy, Hagop M. Kantarjian, Srđan Verstovšek   +17 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source